X-linked acrogigantism (also known as Sotos Syndrome) is a rare genetic disorder that is caused by a mutation in the NSD1 gene. It is characterized by excessive physical growth during childhood, including an unusually large head size, long arms and legs, and a tall stature. Other symptoms may include developmental delays, intellectual disability, and behavioral problems.

The symptoms of X-linked acrogigantism include:

-Growth of the hands, feet, and face that is disproportionate to the rest of the body
-Enlarged jaw
-Large head
-Wide-set eyes
-Thick eyebrows
-Wide nose
-Thick lips
-Deeply set eyes
-High forehead
-Enlarged tongue
-Delayed puberty
-Low muscle tone
-Intellectual disability
-Behavioral problems
-Seizures
-Vision and hearing problems

X-linked acrogigantism is caused by a mutation in the gene GPR101, which is located on the X chromosome. This gene is responsible for producing a protein called GPR101, which is involved in the regulation of growth hormone. Mutations in this gene can lead to an overproduction of growth hormone, resulting in X-linked acrogigantism.

The primary treatment for X-linked acrogigantism is growth hormone therapy. This involves daily injections of recombinant human growth hormone (rhGH) to help reduce the excessive growth and improve the patient's quality of life. Other treatments may include medications to reduce the production of growth hormone, surgery to remove the pituitary tumor, and radiation therapy to shrink the tumor.

1. Being male
2. Having a family history of X-linked acrogigantism
3. Having a mutation in the GPR101 gene
4. Having a mutation in the AIP gene
5. Having a mutation in the CDK4 gene
6. Having a mutation in the POU1F1 gene
7. Having a mutation in the PROP1 gene
8. Having a mutation in the GHRHR gene
9. Having a mutation in the PTPN11 gene
10. Having a mutation in the GNAS gene

There is no cure for X-linked acrogigantism, but there are medications that can help manage the symptoms. These medications include growth hormone-releasing hormone (GHRH) analogs, somatostatin analogs, and dopamine agonists. These medications can help reduce the size of the hands and feet, as well as reduce the risk of developing other complications associated with X-linked acrogigantism.